TITLE:
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

CONDITION:
Nausea

INTERVENTION:
MK0869, aprepitant / Duration of Treatment: 3 days

SUMMARY:

      A multicenter trial to assess the safety and efficacy of an investigational drug in the
      prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed
      solid tumors who will be treated with a chemotherapy regimen that includes cisplatin. The
      study will evaluate the investigational drug for the treatment of CINV during the first
      cycle of treatment with cisplatin.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patient is greater than 18 years of age.

          -  Patient is scheduled to receive his/her first

        course of cisplatin chemotherapy for a solid tumor.

          -  Patient has a prognosis (life expectancy) greater than or equal to 3 months.
      
